<DOC>
	<DOCNO>NCT01935479</DOCNO>
	<brief_summary>The objective study investigate pharmacokinetics , safety , tolerability AK159 administer healthy postmenopausal woman .</brief_summary>
	<brief_title>A Phase I Study AK159 Healthy Postmenopausal Women</brief_title>
	<detailed_description>This study consist two part : Part 1 Part 2 . The Part 1 single-center , randomize , 2-way crossover study investigate pharmacokinetics , safety , tolerability teriparatide single dose AK159 ( 5 level ) estimate relative bioavailability AK159 subcutaneous teriparatide acetate healthy post-menopausal woman . The Part 2 multiple-center , randomize , double-blind , positive- placebo-controlled , parallel study compare pharmacokinetics , bone maker , safety , tolerability teriparatide weekly dos AK159 ( 4 level ) 6 week placebo weekly dos subcutaneous teriparatide acetate healthy post-menopausal woman .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Healthy postmenopausal ethnic Japanese woman At least 45 year age time consent obtain Give voluntary consent write sufficient understanding study . Clinical abnormality identify laboratory test Weight &lt; 40.0 kg Body mass index &lt; 17.5 &gt; =30.5 History disease kidney , liver , heart , brain , organ make ineligible subject Previously receive radiation treatment potentially affect bone Clinical abnormality identify 12lead ECGs perform study center screen period Systolic blood pressure &lt; 90 mmHg Serum calcium level exceed 10.4 mg/dL History contact dermatitis skin disease potentially compromise study evaluation Used drug impact bone metabolism 8week period precede investigational product administration Used bisphosphonate Used teriparatide product</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>AK159 , teriparatide acetate</keyword>
</DOC>